<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743935</url>
  </required_header>
  <id_info>
    <org_study_id>UF 7649</org_study_id>
    <nct_id>NCT03743935</nct_id>
  </id_info>
  <brief_title>Use of Cardiac MRI in Early Stages of STEMI to Predict Left Ventricular Function Recovery and ICD Implantation</brief_title>
  <acronym>STEMI-MR</acronym>
  <official_title>Primary Prevention ICD Implantation in STEMI With Severe Left Ventricular Dysfunction : Input of Early Cardiac MRI in Order to Predict Left Ventricular Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting with STEMI and late revascularization can suffer from severe left
      ventricular dysfunction. Midterm and longterm mortality can be determined by the risk of
      fatal ventricular arrythmias. For this specific population, ESC guidelines currently
      recommend a waiting period of up to 40 days after a STEMI with severe left ventricular
      dysfunction before considering ICD implantation for primary prevention of sudden death.This
      delay is allocated to judge left ventricular recovery.

      This study aims to see whether early cardiac MRI with specific sequences can help predict
      which patients will most probably not recover their left ventricular function and benefit
      from earlier ICD implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ST segment elevation myocardial infarction represent 120 000 annual cases in France. Although
      its mortality has been drastically reduced by primary percutaneous coronary angioplasty
      (PCI), its midterm and longterm outcome in patients presenting initially with severe left
      ventricular (LV) dysfunction depends on the risks of heart failure and sudden death by
      malignant ventricular arrhythmias.

      Many clinical studies such as MADIT I and II, MUSTT and DINAMIT have participated in defining
      which patients should benefit from ICD implantation. These studies were based on evaluation
      of the LV ejection fraction (LVEF) and of the risk of arrhythmia (by electrophysiology or
      holter recordings).

      However, ESC Guidelines recommend a mandatory waiting period of 40 days post-PCI to
      reevaluate LVEF before confirming the need for ICD implantation (LVEF &lt; 35%). Therefore,
      patients are at risk of sudden cardiac death (SCD). during this period.

      The investigators sought to determine whether specific cardiac MRI sequences could help
      predict which patients would eventually recover from their LV dysfunction and therefore
      reduce the risk of SCD by implanting ICD earlier than recommended.

      Patients presenting at our Cardiac ICU with STEMI and severe LV dysfunction (LVEF &lt; 35%), not
      indicated to coronary artery bypass surgery (CABG) and free from initial cardiac arrest or
      severe ventricular arrhythmias, will be included. They will undergo a gadolinium-enhanced
      cardiac MRI during the 1st days of hospitalization with specific sequences to determine
      myocardial zones at risk of non-recovery.

      Initial assessment will also include thorough clinical examination with NYHA class,
      trans-thoracic echocardiography and blood works to evaluate renal function, inflammation,
      signs of heart failyre (BNP and troponin). Patients will be equipped with Lifevests for 6
      weeks and followed-up with the same criteria.

      Ratio of final ICD implantation will then be compared to the MRI criterion to determine
      whether LV recovery could have been predicted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mesure of zones of delayed myocardial transmural enhancement and no-reflow</measure>
    <time_frame>40 days</time_frame>
    <description>Defining the area at risk with Cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mesure of ejection fraction and regional wall motion and thickening</measure>
    <time_frame>40 days</time_frame>
    <description>Defining the area at risk with Cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mesure of extracellular volume</measure>
    <time_frame>40 days</time_frame>
    <description>Defining the area at risk with Cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of CVD events</measure>
    <time_frame>40 days</time_frame>
    <description>Occurrence of major adverse cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of admission to the hospital for heart failure event</measure>
    <time_frame>40 days</time_frame>
    <description>Occurrence of heart failure events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ischemic cardiovascular events</measure>
    <time_frame>40 days</time_frame>
    <description>Occurrence of major adverse cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardiac death</measure>
    <time_frame>40 days</time_frame>
    <description>Occurrence of major adverse cardiac events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute STEMI</condition>
  <condition>Severe Left Ventricular Systolic Dysfunction (Disorder)</condition>
  <arm_group>
    <arm_group_label>Early cardiac MRI post-STEMI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early stages post-STEMI (within the first 5 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gadolinium-enhanced cardiac MRI</intervention_name>
    <description>Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement</description>
    <arm_group_label>Early cardiac MRI post-STEMI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute STEMI within 5 last days with LVEF &lt; 35%

          -  18-80 years old

          -  Admitted to the Cardiac ICU

          -  Consent form

        Exclusion Criteria:

          -  CABG surgery indicated

          -  Contra-indications to MRI

          -  ICD or PPM in place

          -  Follow-up compromised
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Luc PASQUIE, MD-PhD</last_name>
    <phone>0467336187</phone>
    <phone_ext>33</phone_ext>
    <email>jl-pasquie@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Roux, MD</last_name>
    <email>juliejm.roux@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Soltani, Engineer</last_name>
      <email>s-soltani@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Daly C, Kwong RY. Cardiac MRI for myocardial ischemia. Methodist Debakey Cardiovasc J. 2013 Jul-Sep;9(3):123-31. Review.</citation>
    <PMID>24066194</PMID>
  </reference>
  <reference>
    <citation>Perazzolo Marra M, Lima JA, Iliceto S. MRI in acute myocardial infarction. Eur Heart J. 2011 Feb;32(3):284-93. doi: 10.1093/eurheartj/ehq409. Epub 2010 Nov 25. Review.</citation>
    <PMID>21112897</PMID>
  </reference>
  <reference>
    <citation>Schelbert EB, Wong TC. Imaging the area at risk in myocardial infarction with cardiovascular magnetic resonance. J Am Heart Assoc. 2014 Aug 21;3(4). pii: e001253. doi: 10.1161/JAHA.114.001253.</citation>
    <PMID>25146709</PMID>
  </reference>
  <reference>
    <citation>Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016 Nov 30;18(1):89. Review.</citation>
    <PMID>27899132</PMID>
  </reference>
  <reference>
    <citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.</citation>
    <PMID>28886621</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>MRI</keyword>
  <keyword>ICD</keyword>
  <keyword>Sudden death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

